Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
GlobeNewswire
Dupixent^® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in..